zalcitabine has been researched along with ganciclovir in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (34.78) | 18.2507 |
2000's | 5 (21.74) | 29.6817 |
2010's | 9 (39.13) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
Authors | Studies |
---|---|
Bhattacharya, BK; Huffman, JH; Ojwang, JO; Rando, RF; Revankar, GR | 1 |
Breitenbach, JM; Cheng, YC; Drach, JC; Fan, BY; Kern, ER; Ksebati, MB; Lin, JS; Ptak, RG; Qiu, YL; Zemlicka, J | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Andrei, G; Pertusati, F; Pileggi, E; Schols, D; Serpi, M; Snoeck, R | 1 |
Claessens, F; Dehaen, W; Helsen, C; Karypidou, K; Pannecouque, C; Persoons, L; Quevedo, MA; Ribone, SR | 1 |
Andrei, G; Cazin, I; Harej, A; Klobučar, M; Macan, AM; Pavelić, K; Pavelić, SK; Raić-Malić, S; Schols, D; Snoeck, R; Stepanić, V | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Foerster, M; Kastner, U; Neubert, R | 1 |
Morris, DJ | 1 |
Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW | 1 |
Chiang, Y; Drake, RR; Govindarajan, R; Hume, SD; Krisa, S; McMasters, R; Munshi, NC; Rechtin, TM; Saylors, RL | 1 |
AbdelHameed, MH; Dorr, A; Griffy, K; Jung, D; Teitelbaum, P | 1 |
Poscher, M | 1 |
1 review(s) available for zalcitabine and ganciclovir
Article | Year |
---|---|
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
1 trial(s) available for zalcitabine and ganciclovir
Article | Year |
---|---|
The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
Topics: Administration, Oral; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Cross-Over Studies; Cytomegalovirus Retinitis; Drug Interactions; Female; Ganciclovir; HIV Seropositivity; Humans; Male; Stavudine; Zalcitabine | 1999 |
21 other study(ies) available for zalcitabine and ganciclovir
Article | Year |
---|---|
Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Cytomegalovirus; DNA, Viral; Hepatitis B virus; Herpesvirus 1, Human; Humans; Pyrimidine Nucleosides; Structure-Activity Relationship; Vero Cells | 1995 |
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.
Topics: Adenosine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Cell Survival; Chlorocebus aethiops; Cyclopropanes; Guanosine; Hepatitis B virus; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV-1; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Spectrophotometry, Infrared; Vero Cells; Virus Replication | 1998 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
Topics: Antiviral Agents; Cell Line; DNA Viruses; Drug Stability; Humans; Nucleosides; Organophosphonates; Prodrugs; RNA Viruses; Structure-Activity Relationship | 2018 |
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
Topics: Antiviral Agents; Catalytic Domain; Cell Line, Tumor; Coronavirus; Coronavirus 3C Proteases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Protein Binding; Structure-Activity Relationship; Triazoles; Viral Proteins | 2018 |
Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Ascorbic Acid; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles; Viruses | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.
Topics: Animals; Antiviral Agents; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; Female; Flow Cytometry; Ganciclovir; Immunity, Cellular; Male; Nucleotides; Organ Culture Techniques; Pregnancy; Rats; Rats, Wistar; Thymus Gland; Vidarabine; Zalcitabine; Zidovudine | 1992 |
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytomegalovirus; Drug Interactions; Foscarnet; Ganciclovir; HIV-1; Humans; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; RNA, Viral; Thionucleotides; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes.
Topics: Acyclovir; Cell Line; Dose-Response Relationship, Drug; Ganciclovir; Genetic Therapy; Growth Inhibitors; Herpesvirus 1, Human; HIV-1; Humans; Hydroxyurea; Nucleosides; Stavudine; Substrate Specificity; T-Lymphocytes; Thymidine Kinase; Zalcitabine; Zidovudine | 1997 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |